Brean Murray Initiates Coverage on Allergan (AGN) with a Buy
AGN Hot Sheet
Rating Summary:9 Buy, 5 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Brean Murray initiates coverage on Allergan (NYSE: AGN) with a Buy. Price target $75.
Brean analyst says, "AGN's well-balanced portfolio of medical devices and pharmaceuticals, coupled with its recent cost-savings efforts, has allowed it to weather the recession better than many had expected..."
To see all the upgrades/downgrades on shares of AGN, visit our Analyst Ratings page.
Allergan, Inc. is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics and medical devices.
Brean analyst says, "AGN's well-balanced portfolio of medical devices and pharmaceuticals, coupled with its recent cost-savings efforts, has allowed it to weather the recession better than many had expected..."
To see all the upgrades/downgrades on shares of AGN, visit our Analyst Ratings page.
Allergan, Inc. is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics and medical devices.
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- Wedbush Downgrades Maxwell Technologies (MXWL) to Neutral; Elevated Competitive and Supply Chain Risks
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
Create E-mail Alert Related Categories
New CoverageRelated Entities
Brean Murray Carret & Co.Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
